AI Stock Memo: EPRX - Eupraxia - RankAlpha

EPRX

Rating buyAI Memo

Eupraxia

As of 2026-02-19/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-02-19 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

medium

Horizon

—

Key catalyst

Clinical readout / regulatory milestone (assumed window end) • 2027-02-19

Expected move: +101%

Biggest risk

Trial failure, regulatory delays, or financing dilution push valuation below current anchor; liquidity and small-cap volatility amplify downside.

Invalidation

Break below $9 or thesis failure.

What would change my mind?

Successful clinical/regulatory outcomes and a partnership drive re-rating toward the analyst high; upside concentrated in binary milestones.

Research note

Recommendation

buy

Confidence

medium

As of

2026-02-19

Base target

$13

p=60%

Bull target

$19

p=20%

Bear target

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Analyst 12-month consensus targets
Partnership / commercial progress
Successful clinical/regulatory outcomes and a partnership drive re-rating toward the analyst high; upside concentrated in binary milestones.

BearKey bullets

Clinical trial failure
Financing/dilution risk
Low liquidity / high volatility

WatchKey bullets

Clinical readout / regulatory milestone (assumed window end)

Summary

High-level snapshot

Recommendation

buy

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $13 (p=60%)

Bull/Bear spread: +186% / +29%

Vs latest close: Bull +186% · Base +101% · Bear +29%

Scenario probabilities

Bull Target: $19 (p=20%)Base Target: $13 (p=60%)Bear Target: $9 (p=20%)

Commentary

Sentiment is cautiously constructive. The analyst median (base_target $13.345) sits materially above the anchor (7.7), indicating tangible upside; the analyst high (19.0) captures optimistic, binary-outcome upside. Near-term tone is tempered by the recent equity offering and financing/dilution risk, so expect elevated volatility around clinical updates and partnering signals. Our view balances upside from execution against material downside if key catalysts disappoint.

As of 2026-02-19 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Successful clinical/regulatory outcomes and a partnership drive re-rating toward the analyst high; upside concentrated in binary milestones.

Bear Case

Trial failure, regulatory delays, or financing dilution push valuation below current anchor; liquidity and small-cap volatility amplify downside.

Drivers

Scannable catalysts and supporting factors

Analyst 12-month consensus targets
Partnership / commercial progress

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-02-19Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$13.34

Range (USD)

$8.56 - $19.00

Count

Query: Eupraxia Pharmaceuticals Inc Common (EPRX) analyst consensus price target high low average

Eupraxia Pharmaceuticals (EPRX) Stock Forecast & Price Target
Search result #1
According to projections from 1 analysts, the average 12-month price target for Eupraxia Pharmaceuticals is 14.00, with a high estimate of 14 and a low estimate ...
Open source
EPRX Stock Forecast - Eupraxia Pharmaceuticals Inc - Alpha Spread
Search result #2
According to Wall Street analysts, the average 1-year price target for EPRX is 14.96 CAD with a low forecast of 14.14 CAD and a high forecast of 16.11 CAD. Back ...
Open source
Eupraxia Pharmaceuticals Inc. Analyst Estimates - MarketWatch
Search result #3
Stock Price Targets. High, $19.00. Median, $13.00. Low, $10.14. Average, $13.69. Current Price, $8.56. Yearly Numbers. Estimates. EPRX will report 2025 earnings ...
Extracted: $19.00, $13.00, $10.14, $13.69, $8.56Open source
EPRX Stock Forecast 2026 - Eupraxia Pharma Price Targets ...
Search result #4
Based on our analysis of 2 Wall Street analysts, EPRX has a bullish consensus with a median price target of $14.00 (ranging from $11.00 to $19.00). The overall ...
Extracted: $14.00, $11.00, $19.00Open source
Eupraxia Pharmaceuticals Inc. (EPRX) Price Targets
Search result #5
The forecasts for Eupraxia Pharmaceuticals Inc. (EPRX) range from a low of $11 to a high of $19. The average price target represents a increase of $71.02 from ...
Extracted: $11.00, $19.00, $71.02Open source
EUPRAXIA PHARMACEUTICALS INC (EPRX) Stock Analyst Ratings
Search result #6
Analysts have set a mean price target forecast of 10.75. This target is 32.21% above the current price. · EPRX was analyzed by 8 analysts. · In the previous month ...
Open source

Scenarios

Bull Target (Scenario probability)

$19 / p=20% prob

Base Target (Scenario probability)

$13 / p=60% prob

Bear Target (Scenario probability)

$9 / p=20% prob

Price $7 as of 2026-06-02

Nearest Scenario: Bear (∆ 29%)

Targets vs latest close: Bull +186% · Base +101% · Bear +29%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2027-02-19
Clinical readout / regulatory milestone (assumed window end)
No firm public readout date disclosed; conservatively assume window end used for planning (assumption noted) — material binary outcome could move shares materially.
Prob 30.00% • Move 50.00% • Priced-in 10.00%

Short-term Catalysts

Next few weeks

Analyst 12-month consensus targets
2026-05-20
Published analyst consensus (median ~ $13.00–$14.00) implies material upside vs the anchor; sources summarized from market consensus [#SERP-3], [#SERP-1].
Prob 60% • Move 73% • Priced-in 30%

Long-term Catalysts

Months to a year

Partnership / commercial progress
2027-02-19
Potential licensing or commercial deals over the next 12 months could re-rate valuation if achieved; timing uncertain, treated as long catalyst.
Prob 15% • Move 40% • Priced-in 20%

Risks

Clinical trial failure
Financing/dilution risk
Low liquidity / high volatility
Regulatory delay or negative review

Peers

Symbol	Summary
ARWR	Small-cap biotech with pipeline-stage risk; useful comparison for binary-outcome repricing behavior.
AGEN	Early-/mid-stage oncology/immunotherapy peer with similar regulatory-readout sensitivity.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: Eupraxia Pharmaceuticals Inc Common (EPRX) analyst consensus price target high low average
Analysis date: 2026-02-19